~~<i id='C6A054869E'><strike id='C6A054869E'><tt id='C6A054869E'><pre id='C6A054869E'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：entertainment 2025-08-18 17:48:41 Page View：44771

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare Advantage proposed rates disappoint insurers
Next article： Novavax promises a turnaround & Lilly roils the obesity market

Wikipedia

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Sanofi strikes deal with Novavax, boosting the vaccine maker

NICOLASMAETERLINCK/BELGAMAG/AFPviaGettyImagesLONDON—Novavax,thebeleagueredmakerofaCovid-19vaccine,ju

WSS

knowledge

knowledge

explore

Wikipedia

Sanofi strikes deal with Novavax, boosting the vaccine maker